𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mirtazapine for the Treatment of Hot Flushes in Breast Cancer Survivors: A Prospective Pilot Trial

✍ Scribed by Nicoletta Biglia; Franziska Kubatzki; Paola Sgandurra; Riccardo Ponzone; Davide Marenco; Elisa Peano; Piero Sismondi

Book ID
109079560
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
496 KB
Volume
13
Category
Article
ISSN
1075-122X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A prospective randomized trial of doxoru
A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer
✍ Massimo Lopez; Alma Contegiacomo; Patrizia Vici; Concetta Dello Ioio; Luigi Di L πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 481 KB πŸ‘ 2 views

Seventy-six patients with advanced breast cancer were entered into the current study. They were randomized to receive either idarubicin (IDA) 45 mg/m2 orally or doxorubicin (DX) 75 mg/m2 intravenously (IV), both drugs being administered every 3 weeks. Among 37 evaluable patients who received DX trea

A prospective trial of the tnm classific
A prospective trial of the tnm classification of breast cancer by the regional cancer treatment centres in Ontario, 1960–1964
✍ E. N. Mackay; A. H. Sellers πŸ“‚ Article πŸ“… 1970 πŸ› John Wiley and Sons 🌐 French βš– 598 KB

## Abstract As its contribution to the 1960–64 clinical trial of the TNM Classification of breast cancer, The Ontario Cancer Treatment and Research Foundation reviewed in detail the distribution and 5‐year survival of 1,846 female patients classified according to TNM criteria. While further conside

Fulvestrant versus anastrozole for the t
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women : A prospective combined analysis of two multicenter trials
✍ John F. R. Robertson; C. Kent Osborne; Anthony Howell; Stephen E. Jones; Louis M πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 119 KB

## Abstract ## BACKGROUND Fulvestrant (ICI 182,780) is a new type of estrogen receptor (ER) antagonist that down‐regulates the ER and has no known agonist effects. The authors report the prospectively planned combined analysis of data from 2 Phase III trials comparing fulvestrant 250 mg monthly (_